Iteos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, last week announced the appointment of Matthew Call as its Chief Operating Officer. Matthew will also be responsible for business development.

Picture: Henrik Larsson/stock.adobe.com

Although it has only been shown to provide partial protection,  the first-ever malaria vaccine is in testing in Africa – and there are many more hopefuls in the pipeline. Will we soon eradicate one of the most deadly pathogens in human history?

The FDA has given the go-ahead to PharmaMar’s proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line small-cell lung cancer.

Picture: Vetter

Manufacturers respond to stricter regulations with novel approaches.

Aerial image Karolinska Institutet Campus Flemingsberg, 2019. Photographer: barabild.se

Researchers at Karolinska Institutet have discovered a new sensory receptor organ that is able to detect painful mechanical damage, such as pricks and impacts.

Mitosis. ©  By Mysid - Vectorized in CorelDraw by Mysid / https://commons.wikimedia.org/w/index.php?curid=1414818

British researchers have found out what’s going wrong with chromosome segregation in some cancers. 

© Pharming
Pharming NV has paid €17.9m upfront to Novartis AG for an exclusive license to CDZ173, a late stage drug for the treatment of APDS
Group of mesenchymal (green) stem cells migrating in a tooth to further regenerate tissues.
© Media and Communications | University of Plymouth

Researchers have discovered that crosstalk of a newly discovered stem cell population with quiescent stem cells may help repair teeth in the future.

iPSCs derived from somatic cells through a novel reprogramming method. © UCLA Broad Stem Cell Research Center/Plath Lab

Bayer has widened its pipeline in neurology, cardiology, and immunology by acquiring induced pluripotent stem cell specialist BlueRock Therapeutics.

Circulating tumor DNA (ctDNA) is found in serum and plasma fractions from blood. The exact  mechanism of ctDNA release is unknown. Once ctDNA is isolated, it can be sequenced for mutational analysis. © Creative commons licence, RachelJuneWong

Using a platform tailored to patients’ specific cancer mutations, British and US researchers for the first time detected residual disease in breast cancer patients.